Dubai, UAE - Agiomix, the next generation genomics company announced that Dr. Walid Dridi has joined its Medical Board as of June 2019.
“As part of Agiomix’s strategy to attract talented specialists to join its team, we are glad to announce that Dr.Walid Dridi will join our Board of Medical Directors. Dr. Dridi’s experience in running world-class genomics service laboratories will add a wealth to Agiomix capabilities and standards, and his background in cytogenetics will allow Agiomix to offer detailed and comprehensive medical reports to patients and partner laboratories across the region that match the industry’s highest standards”, said Dr. John Clarkson, Board Director of Agiomix.
Dr. Dridi brings 25 years of experience in research and clinical genetics, he heads the Cytogenetics Department of Pathology and Laboratory Medicine at King Fahad Specialist Hospital, Dammam, KSA. Prior to this he worked with Dr. Hakon the Director of the Center of Applied Genomics at Children Hospital of Philadelphia (CHOP), Philadelphia, USA, his work is focused on genomic data design and analysis, with emphasis on machine and deep-learning methods.
Dr. Dridi holds a Doctorate in Medicine (MD) from Algeria, M.Sc. and PhD in Cellular and Molecular Biology from Laval University, Quebec, Canada and has several publications in renowned medical and scientific journals.
Dr. Dridi said “I’m very happy to join the Medical Board of Agiomix. I believe in the company’s vision and can see the persistent need for its services across the region and I have a clear plan to develop the company’s laboratory practices to match the highest international quality standards, and to place the company amongst the best genomics analysis providers in the world.”
About Agiomix FZ-LLC
Agiomix FZ-LLC is a Dubai-headquartered genomics company, focused on offering sequencing and genotyping services to research and clinical customers. Agiomix strives to offer localized, high standard and affordable genomics analysis services with unparalleled counseling and support.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
